Restructuring I was able to reach out to management.
Focus right now is on expanding the company and building a high caliber team.
Options will be used to attract high quality staff and directors as is the case with every successful pharma company on this planet. This is a very logical step. You have to be competitive and offer incentives to attract talent. Options are not harmful to the current SP and those that want to exit at $2 I wouldn't even worry about it. Sernova potentially bringing in more money at $1.5 while incentivizing new talent to come on is not something I'm concerned about.
The dichotomy to be honest is a bit exhausting; it makes no sense to get mad at management for granting options while simultaneously expecting Philp to magically come out with an A-star team. You get what you pay for and options are a great way of paying for success and not having a team milking the payroll. Because the science is real it will attract talent that see the potential and feel they can contribute.
Anyways I see where the frustration comes from but feel its transitory in nature as this company is restructured and a strong team is built.
Sailboat
"Positioning this as binary of whether we are for or against SVA misses the point and does help answer legitimate questions. Especially on the eve of AGM."
These legitimate questions will be answered in time. The previous staff should be acknowledged for bringing this company to where it is today but that was done on a shoestring budget and the depth of experience reflects that. Now that there is a larger budget and clearer path forward in both the science and business you can look at attracting a more experienced team. Take a look at the RD allocations this is really the start of Sernova as a real company. It's unfortunate we don't get our quick fix but it is what it is. The wild card of a collaboration will remain the hope for a major catalyst while other milestones should help those looking to move on to do so.